T2 Biosystems, Inc. is an in vitro diagnostics company engaged in developing a technology platform offering an alternative to diagnostic methodologies. The Company's T2 Magnetic Resonance platform (T2MR) enables detection of pathogens, biomarkers and other abnormalities in a range of unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum and urine, and can detect cellular targets at limits of detection as one colony forming unit per milliliter (CFU/mL). The Company's initial development efforts target sepsis, hemostasis and Lyme disease. T2MR is a miniaturized, magnetic resonance-based approach that measures how water molecules react in the presence of magnetic fields. Its platform detects a range of targets, including molecular targets, such as deoxyribonucleic acid (DNA), immunodiagnostics, such as proteins, and a range of hemostasis measurements. The Company offers T2Dx Instrument (T2Dx) and the T2Candida Panel.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Medical Equipment, Supplies & Distribution - NEC
- Sub-Industry: N/A
- Symbol: NASDAQ:TTOO
- CUSIP: N/A
- Web: www.t2biosystems.com
Capitalization:- Market Cap: $111.6 million
- Outstanding Shares: 30,594,000
Average Prices:- 50 Day Moving Avg: $3.49
- 200 Day Moving Avg: $4.94
- 52 Week Range: $3.02 - $9.26
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -2.99
- P/E Growth: 0.00
Sales & Book Value:- Annual Revenue: $3.92 million
- Price / Sales: 27.08
- Book Value: $0.85 per share
- Price / Book: 4.08
Profitability:- EBIDTA: ($48,860,000.00)
- Net Margins: -1,425.02%
- Return on Equity: -161.43%
- Return on Assets: -69.24%
Debt:- Debt-to-Equity Ratio: 1.56%
- Current Ratio: 6.81%
- Quick Ratio: 6.75%
Misc:- Average Volume: 95,728 shs.
- Beta: 1.61
- Short Ratio: 8.84
Frequently Asked Questions for T2 Biosystems (NASDAQ:TTOO)
What is T2 Biosystems' stock symbol?
T2 Biosystems trades on the NASDAQ under the ticker symbol "TTOO."
How were T2 Biosystems' earnings last quarter?
T2 Biosystems, Inc. (NASDAQ:TTOO) released its quarterly earnings data on Tuesday, May, 2nd. The company reported ($0.48) EPS for the quarter, missing the Zacks' consensus estimate of ($0.47) by $0.01. The business earned $0.94 million during the quarter, compared to analyst estimates of $1.55 million. T2 Biosystems had a negative net margin of 1,425.02% and a negative return on equity of 161.43%. View T2 Biosystems' Earnings History.
When will T2 Biosystems make its next earnings announcement?
Where is T2 Biosystems' stock going? Where will T2 Biosystems' stock price be in 2017?
7 analysts have issued 12 month price objectives for T2 Biosystems' stock. Their predictions range from $4.00 to $12.00. On average, they anticipate T2 Biosystems' stock price to reach $6.83 in the next year. View Analyst Ratings for T2 Biosystems.
What are analysts saying about T2 Biosystems stock?
Here are some recent quotes from research analysts about T2 Biosystems stock:
- 1. According to Zacks Investment Research, "T2 Biosystems, Inc. is an in vitro diagnostics company. It has developed a technology platform that is designed to offer a rapid, sensitive and simple alternative to existing diagnostic methodologies. The Company uses its T2 Magnetic Resonance platform, or T2MR, that enables rapid detection of pathogens, biomarkers and other abnormalities in a variety of unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum and urine, and can detect cellular targets. It operates primarily in the United States. T2 Biosystems, Inc. is headquartered in Lexington, Massachusetts. " (5/6/2017)
- 2. WBB Securities analysts commented, "We Believe that in the not too distant future, doctors in residency will be trained to detect fungal and bacterial infections in hours with 95% accuracy versus the current blood culture standard of two days on average for invasive candidiasis detection, with 38% accuracy. This is the special province that T2 Biosystems, Inc. (TTOO) presently dominates. We are therefore reiterating our Strong Buy Rating and 12-Month Price Target of $12.00." (2/5/2017)
Are investors shorting T2 Biosystems?
T2 Biosystems saw a decrease in short interest in May. As of May 31st, there was short interest totalling 1,278,028 shares, a decrease of 30.7% from the May 15th total of 1,842,908 shares. Based on an average daily volume of 175,188 shares, the short-interest ratio is currently 7.3 days. Approximately 7.4% of the shares of the company are short sold.
Who are some of T2 Biosystems' key competitors?
Some companies that are related to T2 Biosystems include Sientra (SIEN), Transenterix (TRXC), Transenterix (TRXC), Tandem Diabetes Care (TNDM), Bioquell plc (BQE), Cytori Therapeutics (CYTX), Capnia (SLNO), Surgical Innovations Group Plc (SUN), Alliqua BioMedical (ALQA), Lombard Medical (EVAR), InspireMD (NSPR), NeuroMetrix (NURO), CareFusion (CFN), Covidien Ltd (COV), CRH Medical Corp (CRHM), Great Basin Scientific (GBSN) and LDR Holding Corp (LDRH).
Who are T2 Biosystems' key executives?
T2 Biosystems' management team includes the folowing people:
- John McDonough, President, Chief Executive Officer, Director
- Michael J. Cima Ph.D., Co-Founder, Independent Director
- Darlene Deptula-Hicks, Chief Financial Officer, Senior Vice President, Treasurer
- Joanne Spadoro Ph.D., Chief Operations Officer
- Rahul K. Dhanda, Senior Vice President - Corporate Development
- Thomas J. Lowery Ph.D., Chief Scientific Officer
- Michael Gibbs, Vice President, General Counsel
- Michael A. Pfaller M.D., Chief Medical Officer
- Seymour E. Liebman, Director
- John W. Cumming, Independent Director
Who owns T2 Biosystems stock?
T2 Biosystems' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Goldman Sachs Group Inc. (13.90%), Aisling Capital LLC (9.26%), Flagship Pioneering Inc. (6.38%), Polaris Venture Management Co. V L.L.C. (6.13%), Lagoda Investment Management L.P. (5.59%) and Wellington Management Group LLP (4.14%). Company insiders that own T2 Biosystems stock include Aisling Capital Iii Lp, Darlene M Deptula-Hicks, David B Elsbree, Joanne Spadoro, Michael Terrence Gibbs, Polaris Venture Partners V, L, Rahul Dhanda and Thomas J Lowery. View Institutional Ownership Trends for T2 Biosystems.
Who sold T2 Biosystems stock? Who is selling T2 Biosystems stock?
T2 Biosystems' stock was sold by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, Morgan Stanley, Lagoda Investment Management L.P., Essex Investment Management Co. LLC, TIAA CREF Investment Management LLC and United Services Automobile Association. View Insider Buying and Selling for T2 Biosystems.
Who bought T2 Biosystems stock? Who is buying T2 Biosystems stock?
T2 Biosystems' stock was purchased by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Geode Capital Management LLC, Bank of New York Mellon Corp and Goldman Sachs Group Inc.. Company insiders that have bought T2 Biosystems stock in the last two years include Aisling Capital Iii Lp, Darlene M Deptula-Hicks, David B Elsbree, Joanne Spadoro and Michael Terrence Gibbs. View Insider Buying and Selling for T2 Biosystems.
How do I buy T2 Biosystems stock?
Shares of T2 Biosystems can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is T2 Biosystems' stock price today?
One share of T2 Biosystems stock can currently be purchased for approximately $3.47.
MarketBeat Community Rating for T2 Biosystems (NASDAQ TTOO)MarketBeat's community ratings are surveys of what our community members think about T2 Biosystems and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for T2 Biosystems (NASDAQ:TTOO) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 1 Sell Rating, 3 Hold Ratings, 3 Buy Ratings |
| Consensus Rating: | Hold (Score: 2.29) |
| Consensus Price Target: | $6.83 (96.93% upside) |
Analysts' Ratings History for T2 Biosystems (NASDAQ:TTOO)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 5/8/2017 | BTIG Research | Upgrade | Sell -> Neutral | $4.00 | High |  |
| 5/3/2017 | Cantor Fitzgerald | Lower Price Target | Overweight | $7.00 -> $6.00 | High | |
| 3/14/2017 | Morgan Stanley | Downgrade | Equal Weight -> Underweight | $5.00 | High | |
| 2/14/2017 | Canaccord Genuity | Set Price Target | Buy | $9.00 | N/A | |
| 2/5/2017 | WBB Securities | Reiterated Rating | Buy | $12.00 | N/A | |
| 11/10/2016 | Leerink Swann | Reiterated Rating | Market Perform | $5.00 | N/A | |
| 7/9/2016 | Janney Montgomery Scott | Reiterated Rating | Hold | | N/A | |
| 12/22/2015 | Goldman Sachs Group, Inc. (The) | Boost Price Target | Neutral | $13.00 -> $14.00 | N/A | |
| 11/3/2015 | Jefferies Group LLC | Reiterated Rating | Buy -> Fair Value | $21.00 -> $11.48 | N/A | |
(Data available from 6/28/2015 forward)
Earnings History for T2 Biosystems (NASDAQ:TTOO)Earnings History by Quarter for T2 Biosystems (NASDAQ TTOO)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 7/31/2017 | | | | | | | | |
| 5/2/2017 | Q1 2017 | ($0.47) | ($0.48) | $1.55 million | $0.94 million | View | Listen | |
| 11/1/2016 | Q3 | ($0.52) | ($0.51) | $2.03 million | $1.08 million | View | N/A | |
| 8/1/2016 | Q2 | ($0.56) | ($0.58) | $1.53 million | $0.99 million | View | N/A | |
| 5/2/2016 | Q1 | ($0.54) | ($0.55) | $1.01 million | $1.10 million | View | N/A | |
| 2/16/2016 | Q4 | ($0.59) | ($0.56) | $1.21 million | $1.01 million | View | Listen | |
| 11/2/2015 | Q3 | ($0.59) | ($0.57) | $0.66 million | $1.05 million | View | N/A | |
| 8/4/2015 | Q215 | ($0.57) | ($0.54) | $0.34 million | $0.56 million | View | N/A | |
| 5/5/2015 | Q115 | ($0.57) | ($0.53) | $0.22 million | $0.19 million | View | N/A | |
| 2/17/2015 | Q414 | ($0.44) | ($0.45) | | $0.12 million | View | N/A | |
| 11/4/2014 | Q314 | ($0.58) | ($0.71) | $0.10 million | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for T2 Biosystems (NASDAQ:TTOO)2017 EPS Consensus Estimate: ($2.06)
2018 EPS Consensus Estimate: ($1.96)
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 1 | ($0.59) | ($0.59) | ($0.59) |
| Q2 2017 | 1 | ($0.49) | ($0.49) | ($0.49) |
| Q3 2017 | 1 | ($0.49) | ($0.49) | ($0.49) |
| Q4 2017 | 1 | ($0.49) | ($0.49) | ($0.49) |
| Q1 2018 | 1 | ($0.53) | ($0.53) | ($0.53) |
| Q2 2018 | 1 | ($0.50) | ($0.50) | ($0.50) |
| Q3 2018 | 1 | ($0.48) | ($0.48) | ($0.48) |
| Q4 2018 | 1 | ($0.45) | ($0.45) | ($0.45) |
(Data provided by Zacks Investment Research)
Dividend History for T2 Biosystems (NASDAQ:TTOO)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for T2 Biosystems (NASDAQ:TTOO)Insider Ownership Percentage: 38.70%
Institutional Ownership Percentage: 66.66%
Insider Trades by Quarter for T2 Biosystems (NASDAQ:TTOO)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 6/6/2017 | Darlene M Deptula-Hicks | CFO | Buy | 4,000 | $3.58 | $14,320.00 | |
| 6/6/2017 | David B Elsbree | Director | Buy | 10,000 | $3.50 | $35,000.00 | |
| 6/6/2017 | Joanne Spadoro | COO | Buy | 5,000 | $3.50 | $17,500.00 | |
| 6/6/2017 | Michael Terrence Gibbs | General Counsel | Buy | 1,000 | $3.51 | $3,510.00 | |
| 3/15/2017 | David B Elsbree | Director | Buy | 10,000 | $5.97 | $59,700.00 | |
| 6/30/2016 | Rahul Dhanda | SVP | Sell | 3,589 | $8.16 | $29,286.24 | |
| 3/16/2016 | Rahul Dhanda | SVP | Sell | 7,588 | $8.01 | $60,779.88 | |
| 12/9/2015 | Aisling Capital Iii Lp | Major Shareholder | Buy | 307,692 | $9.75 | $2,999,997.00 | |
| 12/9/2015 | David B Elsbree | Director | Buy | 10,000 | $9.75 | $97,500.00 | |
| 7/24/2015 | Polaris Venture Partners V, L. | Major Shareholder | Sell | 15,399 | $15.04 | $231,600.96 | |
| 7/22/2015 | Polaris Venture Partners V, L. | Major Shareholder | Sell | 14,999 | $15.22 | $228,284.78 | |
| 7/21/2015 | Polaris Venture Partners V, L. | Major Shareholder | Sell | 14,999 | $15.42 | $231,284.58 | |
| 7/20/2015 | Polaris Venture Partners V, L. | Major Shareholder | Sell | 14,999 | $16.05 | $240,733.95 | |
| 7/17/2015 | Polaris Venture Partners V, L. | Major Shareholder | Sell | 44,997 | $16.26 | $731,651.22 | |
| 7/14/2015 | Polaris Venture Partners V, L. | Major Shareholder | Sell | 29,998 | $16.57 | $497,066.86 | |
| 7/10/2015 | Polaris Venture Partners V, L. | Major Shareholder | Sell | 44,997 | $16.25 | $731,201.25 | |
| 7/10/2015 | Thomas J Lowery | Insider | Sell | 2,000 | $16.03 | $32,060.00 | |
| 7/7/2015 | Polaris Venture Partners V, L. | Major Shareholder | Sell | 44,997 | $15.91 | $715,902.27 | |
| 7/1/2015 | Polaris Venture Partners V, L. | Major Shareholder | Sell | 44,997 | $16.09 | $724,001.73 | |
| 6/30/2015 | Polaris Venture Partners V, L. | Major Shareholder | Sell | 14,999 | $16.22 | $243,283.78 | |
| 6/29/2015 | Polaris Venture Partners V, L. | Major Shareholder | Sell | 14,999 | $16.28 | $244,183.72 | |
| 6/26/2015 | Polaris Venture Partners V, L. | Major Shareholder | Sell | 44,997 | $17.08 | $768,548.76 | |
| 6/23/2015 | Polaris Venture Partners V, L. | Major Shareholder | Sell | 29,998 | $18.18 | $545,363.64 | |
| 6/22/2015 | Polaris Venture Partners V, L. | Major Shareholder | Sell | 14,999 | $18.22 | $273,281.78 | |
| 6/18/2015 | Thomas J Lowery | Insider | Sell | 1,000 | $18.65 | $18,650.00 | |
| 6/12/2015 | Michael J Cima | Director | Buy | 1,000 | $18.91 | $18,910.00 | |
| 6/12/2015 | Thomas J Lowery | Insider | Sell | 1,471 | $18.55 | $27,287.05 | |
| 5/8/2015 | Michael A Pfaller | Insider | Sell | 15,440 | $16.31 | $251,826.40 | |
| 4/20/2015 | Thomas J Lowery | Insider | Sell | 1,000 | $18.43 | $18,430.00 | |
| 3/4/2015 | David B Elsbree | Director | Buy | 1,450 | $15.05 | $21,822.50 | |
| 11/13/2014 | David B Elsbree | Director | Buy | 1,500 | $14.75 | $22,125.00 | |
| 8/12/2014 | Aisling Capital Iii Lp | Major Shareholder | Buy | 454,545 | $11.00 | $4,999,995.00 | |
| 8/12/2014 | Sarah O Kalil | COO | Buy | 15,000 | $11.00 | $165,000.00 | |
| 8/12/2014 | Thomas J Carella | Director | Buy | 909,090 | $11.00 | $9,999,990.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for T2 Biosystems (NASDAQ:TTOO)
Latest Headlines for T2 Biosystems (NASDAQ:TTOO)
| Source: |
|
| Date | Headline |
|---|
 | T2 Biosystems, Inc. (TTOO) Forecasted to Earn FY2018 Earnings of ($1.40) Per Share
www.americanbankingnews.com - June 26 at 7:51 AM |
| $790,000.00 in Sales Expected for T2 Biosystems, Inc. (TTOO) This Quarter
www.americanbankingnews.com - June 24 at 9:30 AM |
| -$0.45 EPS Expected for T2 Biosystems, Inc. (TTOO) This Quarter
www.americanbankingnews.com - June 22 at 11:02 AM |
| T2 Biosystems, Inc. (TTOO) Receives Average Recommendation of "Hold" from Analysts
www.americanbankingnews.com - June 20 at 9:21 AM |
 | T2 Biosystems Chief Scientific Officer Tom Lowery to Present at BIO 2017 Convention
finance.yahoo.com - June 19 at 8:50 AM |
| Financial Analysis: Synergetics USA (SURG) & T2 Biosystems (TTOO)
www.americanbankingnews.com - June 17 at 7:44 AM |
| Short Interest in T2 Biosystems, Inc. (TTOO) Decreases By 30.7%
www.americanbankingnews.com - June 14 at 7:12 AM |
| Darlene M. Deptula-Hicks Buys 4,000 Shares of T2 Biosystems Inc (TTOO) Stock
www.americanbankingnews.com - June 8 at 8:40 PM |
| Insider Buying: T2 Biosystems Inc (TTOO) COO Purchases 5,000 Shares of Stock
www.americanbankingnews.com - June 8 at 8:20 PM |
| T2 Biosystems Inc (TTOO) Director Purchases $35,000.00 in Stock
www.americanbankingnews.com - June 8 at 8:20 PM |
| T2 Biosystems to Present at the 2017 Marcum Microcap Conference
finance.yahoo.com - June 8 at 4:05 PM |
 | T2 Biosystems (TTOO) Presents New T2Sepsis Solution Clinical & Economic Results at ASM Microbe 2017 Conference
www.streetinsider.com - June 8 at 1:32 AM |
| T2 Biosystems Announces New T2Sepsis Solution™ Clinical and Economic Results Presented by Leading Experts at ASM Microbe 2017 Conference
finance.yahoo.com - June 7 at 9:24 AM |
| Study Published in the Journal of Clinical Microbiology Highlights Detection of Lyme Disease-Causing Bactera in Blood Using T2 Biosystems’ T2MR® Technology
finance.yahoo.com - June 2 at 2:37 AM |
| Zacks: Brokerages Anticipate T2 Biosystems Inc (TTOO) Will Post Quarterly Sales of $790,000.00
www.americanbankingnews.com - May 31 at 2:50 PM |
| T2 Biosystems to Present at the Jefferies 2017 Global Healthcare Conference
finance.yahoo.com - May 30 at 8:24 AM |
| -$0.45 EPS Expected for T2 Biosystems Inc (TTOO) This Quarter
www.americanbankingnews.com - May 29 at 8:24 AM |
| T2 Biosystems Inc (TTOO) Given Consensus Rating of "Hold" by Brokerages
www.americanbankingnews.com - May 26 at 9:39 AM |
| ETFs with exposure to T2 Biosystems, Inc. : May 25, 2017
finance.yahoo.com - May 26 at 7:58 AM |
| T2 Biosystems Announces Presentations at ASM Microbe 2017 Conference
finance.yahoo.com - May 24 at 8:39 AM |
| Henry Ford Health System to Present Webinar on Positive Clinical Impact of T2 Biosystems’ T2Candida® Panel
finance.yahoo.com - May 19 at 1:23 PM |
| FY2017 EPS Estimates for T2 Biosystems Inc (TTOO) Decreased by Analyst
www.americanbankingnews.com - May 12 at 11:46 AM |
| ETFs with exposure to T2 Biosystems, Inc. : May 11, 2017
finance.yahoo.com - May 12 at 2:49 AM |
| T2 Biosystems, Inc. :TTOO-US: Earnings Analysis: Q1, 2017 By the Numbers : May 10, 2017
finance.yahoo.com - May 10 at 3:21 PM |
| T2 Biosystems Inc (TTOO) Raised to "Neutral" at BTIG Research
www.americanbankingnews.com - May 8 at 10:16 AM |
| T2 Biosystems Inc (TTOO) Upgraded to "Hold" by Zacks Investment Research
www.americanbankingnews.com - May 6 at 7:34 AM |
| T2 Biosystems Inc (TTOO) Expected to Announce Quarterly Sales of $790,000.00
www.americanbankingnews.com - May 5 at 1:38 PM |
| Leerink Swann Equities Analysts Lift Earnings Estimates for T2 Biosystems Inc (TTOO)
www.americanbankingnews.com - May 5 at 7:36 AM |
| T2 Biosystems (TTOO) Receives News Impact Rating of 0.01
www.americanbankingnews.com - May 4 at 12:12 PM |
| T2 Biosystems, Inc (TTOO) PT Lowered to $6 at Cantor Fitzgerald; 'Lower Than Expected 1Q17 Results, T2Bacteria Progresses'
www.streetinsider.com - May 3 at 11:42 PM |
| T2 Biosystems Inc (TTOO) Expected to Post Earnings of -$0.46 Per Share
www.americanbankingnews.com - May 3 at 6:02 PM |
| T2 Biosystems Inc (TTOO) Releases Earnings Results, Misses Expectations By $0.01 EPS
www.americanbankingnews.com - May 3 at 5:00 PM |
| T2 Biosystems Reports First Quarter 2017 Results and Corporate Update
finance.yahoo.com - May 3 at 10:09 AM |
| Edited Transcript of TTOO earnings conference call or presentation 2-May-17 8:30pm GMT
finance.yahoo.com - May 3 at 10:09 AM |
 | T2 Biosystems reports 1Q loss
marketbeat.com - May 2 at 6:13 PM |
| Investor Network: T2 Biosystems, Inc. to Host Earnings Call
finance.yahoo.com - May 2 at 8:43 AM |
| T2 Biosystems (TTOO) Names Darlene Deptula-Hicks as CFO
www.streetinsider.com - May 1 at 7:29 PM |
| T2 Biosystems (TTOO) Receives News Impact Rating of 0.10
www.americanbankingnews.com - May 1 at 5:40 PM |
| Short Interest in T2 Biosystems Inc (TTOO) Declines By 7.3%
www.americanbankingnews.com - May 1 at 4:58 PM |
| T2 Biosystems Inc (TTOO) Receives Consensus Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - May 1 at 1:00 PM |
| T2 Biosystems Names Darlene Deptula-Hicks as Chief Financial Officer
finance.yahoo.com - May 1 at 10:41 AM |
| T2 Biosystems Inc (TTOO) Set to Announce Earnings on Tuesday
www.americanbankingnews.com - April 30 at 9:08 AM |
| T2 Biosystems (TTOO) Receiving Positive News Coverage, Study Finds
www.americanbankingnews.com - April 28 at 2:36 PM |
| ETFs with exposure to T2 Biosystems, Inc. : April 25, 2017
finance.yahoo.com - April 25 at 7:19 PM |
| T2 Biosystems (TTOO) Earns Media Impact Rating of 0.34
www.americanbankingnews.com - April 25 at 4:16 PM |
| T2 Biosystems (TTOO) Given Daily Coverage Optimism Score of -0.02
www.americanbankingnews.com - April 22 at 11:59 AM |
| T2 Biosystems to Host Symposium at 27th European Congress of Clinical Microbiology and Infectious Diseases
finance.yahoo.com - April 19 at 10:42 PM |
| T2 Biosystems (TTOO) Earns Daily News Sentiment Score of -0.12
www.americanbankingnews.com - April 16 at 10:41 AM |
| T2 Biosystems Inc (TTOO) Expected to Announce Quarterly Sales of $1.55 Million
www.americanbankingnews.com - April 14 at 1:40 PM |
| T2 Biosystems Inc (TTOO) Lifted to "Hold" at Zacks Investment Research
www.americanbankingnews.com - April 14 at 7:58 AM |
T2 Biosystems (TTOO) Chart for Wednesday, June, 28, 2017
